We are international
Donate
• videos TEXT SIZE   



XIIth International Myeloma Workshop, Day 3, February 28, 2009

  • 08:15-10:15 Consensus Panel
  • 10:30-12:30 Transplant
  • 13:30-15:00 Clinical - Phase II/III Studies
  • 13:30-15:00 Clinical Care
  • 13:30-15:00 Clinical - Basic Biology - Research II
  • 15:30-17:30 Future Directions and Strategies in the Evaluation and Treatment of Clonal Plasma Cell Disorders (Sponsored by Celgene)
Complete Program Listing

2009 IMW Saturday Sessions

Consensus Panel Presentations
Consensus Panel Session Introduction
XIIth International Myeloma Workshop in Washington, DC
Nikhil Munshi, M.D.
Dana Farber Cancer Institute
Boston MA

Guidelines for the Uniform Reporting of Clinical Trials in Myeloma: Report of the IMW Consensus Panel
XIIth International Myeloma Workshop in Washington, DC
Vincent Rajkumar, M.D.
Mayo Clinic, Rochester, Minnesota
and
Jesus San Miguel, M.D.
Hospital Clinico Universitario, Universidad de Salamanca, Salamanca, Spain

Guidelines for Stratification of Risk In Multiple Myeloma: Report of the IMW Consensus Panel
XIIth International Myeloma Workshop in Washington, DC
Nikhil Munshi, M.D.
Dana Farber Cancer Institute, Boston, Massachusetts
and
Herve Avet-Loiseau, M.D.
Institut de Biologie, Nantes, France

Guidelines for Standard Investigative Work-Up in Myeloma: Report of the IMW Consensus Panel
XIIth International Myeloma Workshop in Washington, DC
Meletios Dimopoulos, M.D.
Alexandra Hospital, Athens, Greece
and
Sundar Jagannath, M.D.
St. Vincent's Comprehensive Cancer Center, New York, New York

Statistical Issues in the Design and Analysis of Clinical Trials in Myeloma
XIIth International Myeloma Workshop in Washington, DC
John Crowley, PhD
Cancer Research and Biostatistics (CRAB)
Seattle, Washington

Multiple Myeloma - Transplant
New Mobilization and Conditioning Strategies
XIIth International Myeloma Workshop in Washington, DC
Sergio Giralt, M.D.
MD Anderson Cancer Center
Houston, Texas

Timing of Transplant in the Era of New Drugs
XIIth International Myeloma Workshop in Washington, DC
Donna Weber, M.D.
MD Anderson Cancer Center
Houston, Texas

Number - Single vs Double
XIIth International Myeloma Workshop in Washington, DC
Michele Cavo, M.D.
Istituto "Seràgnoli"
Bologna, Italy

Total Therapy
XIIth International Myeloma Workshop in Washington, DC
Bart Barlogie, M.D.
University of Arkansas for Medical Science
Little Rock, Arkansas

Allogeneic Transplant in Multiple Myeloma - Allografting for Myeloma: Mini? Maxi? Or Something in Between?
XIIth International Myeloma Workshop in Washington, DC
William Bensinger, M.D.
Fred Hutchinson Cancer Research Center
Seattle, Washington

Post Transplant Maintenance
XIIth International Myeloma Workshop in Washington, DC
Thierry Facon, M.D.
Hôpital Claude Huriez
Lille, France

Oral Presentations – Clinical – Phase II/III Studies - II
Note: The video for Dr. Offidani's presentation is incomplete. As soon as a complete copy is located, we will post his talk.
HOVON-50 Final Analysis of Thalidomide Combined with Adriamycine, Dexamethasone and HDM
XIIth International Myeloma Workshop in Washington, DC
Henk Lokhorst, M.D.
University Hospital
Rotterdam, Netherlands

Long-term Follow-up Results of IFM9903 and IFM9904 Rrials: RIC versus ASCT
XIIth International Myeloma Workshop in Washington, DC
Phillipe Moreau, M.D.
Hopital de Nantes
Nantes, France

Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation in Myeloma – a Prospective Trial
XIIth International Myeloma Workshop in Washington, DC
Gösta Gahrton, M.D.
Karolinska Institute
Huddinge University Hospital
Stockholm, Sweden

A Phase III Study of MEL200 versus MEL100 in Newly Diagnosed Myeloma Young Patients
XIIth International Myeloma Workshop in Washington, DC
Federica Cavallo, M.D.
Ospedale San Giovanni Battista
Torino, Italy

A Randomized Phase I Study of Melphalan and Bortezomib for Autologous Transplant in Myeloma
XIIth International Myeloma Workshop in Washington, DC
Jonathan Kaufman, M.D.
Winship Cancer Institute
Emory University
Atlanta, Georgia

Future Directions and Strategies in the Evaluation and Treatment of Clonal Plasma Cell Disorders
Monoclonal Gammopathy of Undetermined Significance (MGUS): A Disease in Progression
XIIth International Myeloma Workshop in Washington, DC
Ola Landgren, M.D.
National Cancer Institute
Bethesda, Maryland

Immunophenotyping of Plasma Cell Disorders
XIIth International Myeloma Workshop in Washington, DC
Jesus San Miguel, M.D.
University Hospital
Salamanca, Spain

Can We Treat MGUS and Smouldering Myeloma?
XIIth International Myeloma Workshop in Washington, DC
Jean-Luc Harousseau, M.D.
Hopital Hotel Dieu
Nantes, France

Novel Agents in the Treatment of POEMS (Polyneuropathy, Organomegaly, Endocrinopathy, Multiple Myeloma, and Skin Changes)
XIIth International Myeloma Workshop in Washington, DC
Angela Dispenzieri, M.D.
Mayo Clinic
Rochester, Minnesota

Understanding Pathogenesis to Improve Care in Amyloidosis
XIIth International Myeloma Workshop in Washington, DC
Giampaolo Merlini, M.D.
University of Pavia
Pavia, Italy

Improving Care for Patients with Amyloidosis
XIIth International Myeloma Workshop in Washington, DC
V. Sanchorawala, M.D.
Boston University Medical Center
Boston, Massachusetts

Novel Treatment Options in Waldenstrom Macroglobulinaemia
XIIth International Myeloma Workshop in Washington, DC
Meletios Dimopoulos, M.D.
University of Athens Medical School
Athens, Greece

Pathogenesis, Biology and Diagnosis of Waldenstrom Macroglobulinaemia
XIIth International Myeloma Workshop in Washington, DC
Steven Treon, M.D.
Dana-Farber Cancer Institute
Boston, Massachusetts